Aclaris Therapeutics (ACRS) Other Non-Current Liabilities (2016 - 2026)

Aclaris Therapeutics' Other Non-Current Liabilities history runs 11 years deep, the most recent figure standing at $1.4 million for Q1 2026.

• On a quarterly basis, Other Non-Current Liabilities fell 67.13% year-over-year to $1.4 million in Q1 2026; TTM through Mar 2026 was $1.4 million, a 67.13% decrease from a year earlier, with the FY2025 full-year figure at $11.0 million, up 147.8% from the prior year.
• Other Non-Current Liabilities declined to $1.4 million in Q1 2026 per ACRS's latest filing, from $11.0 million in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $33.1 million in Q4 2022 and bottomed at $1.4 million in Q1 2026.
• The 5-year median for Other Non-Current Liabilities is $9.2 million (2024), against an average of $13.6 million.
• Across the five-year window, Other Non-Current Liabilities soared 794.44% in 2022 and tumbled 92.95% in 2023, its largest moves.
• Year by year, Other Non-Current Liabilities stood at $33.1 million in 2022, then sank by 90.71% to $3.1 million in 2023, then soared by 44.4% to $4.4 million in 2024, then soared by 147.8% to $11.0 million in 2025, then plunged by 87.13% to $1.4 million in 2026.
• Per Business Quant, the three latest ACRS Other Non-Current Liabilities figures stand at $1.4 million (Q1 2026), $11.0 million (Q4 2025), and $1.7 million (Q3 2025).